ONCO
Onconetix IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$7.96M
P/E Ratio
—
EPS
$-82.80
Beta
3.63
52W High
$53.55
52W Low
$0.57
50-Day MA
$2.09
200-Day MA
$10.33
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Onconetix Inc
Onconetix Inc. is a leading biotechnology company at the forefront of revolutionizing cancer care through innovative diagnostic and therapeutic solutions. Utilizing a proprietary technology platform, the firm emphasizes early detection and personalized treatment approaches for a range of malignancies, aiming to fulfill a vital need in oncology. With a strong and diverse pipeline, Onconetix is strategically positioned to address the rising demand for effective cancer therapies, significantly improving patient outcomes through its advanced research and development efforts in the dynamic landscape of cancer treatment.
Fundamentals
| Revenue (TTM) | 815,370 |
| Gross Profit (TTM) | 632,910 |
| EBITDA | $-6.33M |
| Operating Margin | -422.10% |
| Return on Equity | -115.50% |
| Return on Assets | -14.90% |
| Revenue/Share (TTM) | $4.35 |
| Book Value | $50.53 |
| Price-to-Book | 0.51 |
| Price-to-Sales (TTM) | 9.77 |
| EV/Revenue | 3.424 |
| EV/EBITDA | -0.47 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -57.40% |
| Shares Outstanding | $11.46M |
| Float | 653,840 |
| % Insiders | 10.16% |
| % Institutions | 2.71% |
Data last updated: 5/1/2026